Considerations for Choosing Boosted PI vs INSTI-Based Therapy

When choosing between INSTI-based and boosted PI–based therapy, the following considerations might be taken into account:

• Dosing
  • There is now 1 boosted PI–based coformulated single-tablet regimen, cobicistat/darunavir/emtricitabine/tenofovir AF. The boosted PIs atazanavir/cobicistat and cobicistat/darunavir are also coformulated, but the NRTI pair must be given separately
  ...

  Action required

  • Login now to access all of your entitled content
    or
  • View additional options to gain access to this content